Medifast (MED) Down 5.7% Since Last Earnings Report: Can It Rebound?

Core Viewpoint - Medifast's recent earnings report indicates a significant decline in both revenue and earnings, raising concerns about the company's future performance and market position [2][3][4]. Financial Performance - Medifast reported a fourth-quarter loss of $1.65 per share, which was wider than the Zacks Consensus Estimate of a loss of 76 cents per share [3]. - Net revenues for the quarter were $75.1 million, reflecting a year-over-year decline of 36.9%, although it exceeded the Zacks Consensus Estimate of $70.8 million [4]. - The average revenue per active earning OPTAVIA Coach increased by 6.2% year over year to $4,664, despite the overall revenue decline [4]. Operational Challenges - The total number of active earning OPTAVIA coaches decreased by 40.6% year over year to 16,100, attributed to client acquisition challenges and increased competition from GLP-1 medications in the weight-loss market [5]. - Gross profit fell to $52.1 million, down 40.9% year over year, with a gross margin of 69.4%, compared to 74.1% in the prior year [6]. Cost Management - Selling, general, and administrative expenses decreased by 31.5% year over year to $59.9 million, primarily due to lower sales volumes and fewer active coaches [7]. - Despite the decline in absolute terms, SG&A expenses rose to 79.8% of revenue, reflecting reduced fixed-cost leverage and higher event and restructuring costs [8]. Financial Health - As of December 31, 2025, Medifast had cash, cash equivalents, and investment securities totaling $167.3 million, with no debt and total shareholders' equity of $198.9 million [9]. Future Outlook - For the first quarter of 2026, Medifast expects revenues between $65 million and $80 million, with a loss per share projected between 15 cents and 70 cents [11]. - For the full year 2026, revenues are anticipated to range from $270 million to $300 million, with a loss per share expected between $1.55 and $2.75 [11]. Market Sentiment - Following the earnings release, there has been a downward trend in estimates, with the consensus estimate shifting by -358.33% [12]. - Medifast currently holds a Zacks Rank of 4 (Sell), indicating expectations of below-average returns in the coming months [14].